Abstract:Key PointsFocal adhesion kinase (FAK) is a scaffold and kinase protein that binds to itself and cellular partners through its four-point-one, ezrin, radixin, moesin (FERM) domain. Recent data on FAK structure and the sequence of activation have been deduced, largely from crystallographic and biosensor studies. These data have revealed that the activation sequence involves the release of FERM–kinase interactions, subsequent conformational changes, protein binding and key phosphorylation events at specific subcellular locations.The FERM domain of FAK binds to cellular protein and lipid partners, and these are variously involved in catalytic activation and/or recruitment of FAK into macromolecular complexes in cells — predominantly at cortical adhesion structures, but also in the nucleus.Among cytoplasmic FAK FERM domain binding partners recognized thus far are: phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2; generated by the action of phosphatidylinositol-4-phosphate 5-kinase type-1γ (PtdIns(4)P5KIγ)), which binds to the FERM domain and may trigger the activation cascade, perhaps along with molecular clustering, actin-related protein 3 (ARP3), receptor for activated kinase C 1 (RACK1), epidermal growth factor receptor (EGFR), c-Met, ezrin, epithelial and endothelial tyrosine kinase (ETK; also known as BMX), possibly insulin receptor substrate 1 (IRS1), JNK/SAPK-associated protein 1 (JSAP1; also known as JIP3) , and the β subunits of integrin cell–extracellular matrix receptors.FAK is required for optimal signalling from the tyrosine kinase receptors EGFR and c-Met, and modulates cortical actin and nascent adhesions by binding to the ARP2/3 complex and the molecular scaffold RACK1. The FERM domain is implicated in these important FAK functions.The FERM domains of FAK and PYK2 also bind to the tumour suppressor protein p53 and its regulator MDM2 in the nucleus on receipt of stress signals such as cell detachment. p53 degradation and survival can be promoted through these FERM-mediated interactions.The findings above imply that the FAK FERM domain may control and coordinate cellular responses at the cell cortex and in the nucleus, potentially linking regulation of cell migration with the life and death choices that cells have to make. We speculate that the FERM domain may act as a 'sensor' and 'shuttle' of information and events occurring in and between distinct subcellular locations. From data in the literature on other FERM domain-containing proteins (FDCPs) and from sequence gazing, we speculate that a 'cortex to nuclear' information shuttle may be a more general function of FERM domains in biology, which could be exploited for therapy.

New insights into FAK structure and function in focal adhesions

Structural basis of Focal Adhesion Kinase activation on lipid membranes

Focal Adhesion Kinase: a regulator of focal adhesion dynamics and cell movement

FAK dimerization controls its kinase-dependent functions at focal adhesions

Focal adhesion kinase: from biological functions to therapeutic strategies

Focal adhesion kinase signaling - tumor vulnerabilities and clinical opportunities

FAK expression regulation and therapeutic potential

Development of Novel Focal Adhesion Kinase (FAK) Inhibitors for Targeting Cancer: Structural Insights and Therapeutic Potential

Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex

Dynamic conformational changes in the FERM domain of FAK are involved in focal-adhesion behavior during cell spreading and motility

The FERM domain: organizing the structure and function of FAK

Chapter 3 FAK Expression

In-situ coupling between kinase activities and protein dynamics within single focal adhesions

Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes

Focal Adhesion Kinase (FAK) and c-Src Dependent Signal Transduction in Cell Adhesion

Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis

Signal transduction by focal adhesion kinase in cancer

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders

FAK-Dependent Cell Motility and Cell Elongation

Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy

Protein Kinase A is a Functional Component of Focal Adhesions